Management continues to anticipate the presentation of three-year OpRegen trial data in June 2025, with Culley expressing hope it will “provide additional conviction in our approach.” There remains no ...
Rapid developments in gene-modified cell therapies, especially CAR T-cell therapies, has increased demand for fast and reliable analytics methods for research, in-process development, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results